Overview

Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
0
Participant gender:
All
Summary
Lowering LDL cholesterol by statins has been proven to be associated with reduction of proinflammatory regulators e.g. activation of the transcription factor NF-ĸB. Up to now the effects of newer cholesterol lowering agents such as ezetemibe with respect to their anti-inflammatory potential are less intensively studied. Therefore the investigators analyzed whether equipotent LDL-lowering therapy with simvastatin alone and in combination with ezetimibe have comparable effects on NF-ĸB-activation in peripheral blood mononuclear cells (PBMCs) of patients with type 2 diabetes.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Heidelberg University
Treatments:
Ezetimibe
Simvastatin
Criteria
Inclusion Criteria:

- 35 to 80 years old

- type 2 diabetes

- HbA1c value between 6.0 % and 9.0 %

- elevated LDL-c values > 100 mg/dl with no lipid lowering treatment within the last six
month

Exclusion Criteria:

- refused informed consent